Clinical Trials
10 trialsNCT07398599 2026-04-23
Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
Second Affiliated Hospital of Nanchang University
Phase NA Recruiting
NCT06812871 2026-04-02
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
Sun Yat-sen University
Phase 2 Completed
NCT06663306 2026-03-02
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Shanghai Chest Hospital
Phase 1 Recruiting
NCT06643000 2025-03-06
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
Henan Cancer Hospital
Phase NA Recruiting
NCT06728865 2024-12-11
Better Brain
Sun Yat-sen University
Phase 2 Recruiting
NCT04944069 2021-06-29
ATTRACT
Second Affiliated Hospital of Nanchang University
Phase NA Unknown
NCT00924820 2020-12-31
A Pilot Study of Bevacizumab for Neoplastic Meningitis
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04425681 2020-06-11
OWBLM
Second Affiliated Hospital of Nanchang University
Phase 2 Unknown
NCT04148898 2019-11-04
OWONBNSCLCLM
Second Affiliated Hospital of Nanchang University
Phase 2 Unknown
NCT01281696 2013-10-16
Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis
National Taiwan University Hospital
Phase 2 Completed